Friday, March 31

Drug developed with AI will start clinical trials | Digital Trends Spanish

A Hong Kong-based biotech company called Insilico Medicine is to start the first phase of clinical trials for a drug developed with artificial intelligence to treat a lung disease.

The drug, created with deep learning algorithms, was designed to treat idiopathic pulmonary fibrosis (IPF) and will be tested in 80 healthy volunteers.

The test subjects will be divided into ten groups, of which five will receive single doses in increasing amounts; the other five will also receive multiple doses in increasing amounts.

The company said that the objective of the first phase of clinical trials is to establish the maximum dose to start phase two, in which the drug will be tested in patients with idiopathic pulmonary fibrosis.

The drug developed by Insilico Medicine is part of a trend in biotechnology, which seeks to use deep learning algorithms to detect patterns in large databases that can be used to develop treatments or drugs against diseases.

Large technology companies, such as IBM, have artificial intelligence algorithms dedicated to the formulation of drugs such as antibiotics.

“Modern deep learning technologies allow us to perform target identification using longitudinal biological data from healthy subjects and make inferences in a variety of diseases,” said in a statement Alex Zhavoronkovfounder and CEO of Insilico Medicine.

The company detailed that the drug development process took around 18 months.

Publisher Recommendations